Article
Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda.
AIDS (London, England) - 1 Jun 2021
McCluskey Suzanne M, Kamelian Kimia, Musinguzi Nicholas, Kigozi Simone, Boum Yap, Bwana Mwebesa B, Muzoora Conrad, Brumme Zabrina L, Carrington Mary, Carlson Jonathan, Foley Brian, Hunt Peter W, Martin Jeffrey N, Bangsberg David R, Harrigan P Richard, Siedner Mark J, Haberer Jessica E, Lee Guinevere Q
Abstract excerpt
OBJECTIVE: Dolutegravir (DTG) is now a preferred component of first-line antiretroviral therapy (ART). However, prevalence data on natural resistance to integrase inhibitors [integrase strand transfer inhibitors (INSTIs)] in circulating non-subtype B HIV-1 in sub-Saharan Africa is scarce. Our objective is to report prevalence of pre-treatment integrase polymorphisms associated with resistance to INSTIs in an...
Topics
Join the communities discussing this publication.
